Grant: Proof of Principle Program - Phase I
University of Toronto
$85,712.00
Arrays of constrained histone tail mimetics for the development of epigenetic anticancer drugs
EF 2010-11
Résumé
There has been increasing interest in anti-cancer drugs that are peptides and proteins, as opposed to traditional drugs which are small chemical molecules. Peptides and proteins appear promising because they are made up of amino acids, which humans naturally have, and they are therefore less likely to cause unwanted side effects. The challenge with using peptides and proteins is that they are not stable for long periods of time in the bloodstream and they do not readily enter cancer cells. We have been able to produce protein therapeutics with increased stability and demonstrated their successful entry into cells. We need further funding to commercialize this discovery and develop increasingly effective cancer therapies.
Programme
Proof of Principle Program - Phase I
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
228126
Name
Yudin Andrei
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Arrays of constrained histone tail mimetics for the development of epigenetic anticancer drugs
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$85,712
Cihrequipment2
$74,288
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Bromodomains; Cancer; Cyclic Peptides; Epigenetics; Histone Acetylation; Library Synthesis; Macrocycles; Peptide Arrays; Screening; Signaling
Abstract
There has been increasing interest in anti-cancer drugs that are peptides and proteins, as opposed to traditional drugs which are small chemical molecules. Peptides and proteins appear promising because they are made up of amino acids, which humans naturally have, and they are therefore less likely to cause unwanted side effects. The challenge with using peptides and proteins is that they are not stable for long periods of time in the bloodstream and they do not readily enter cancer cells. We have been able to produce protein therapeutics with increased stability and demonstrated their successful entry into cells. We need further funding to commercialize this discovery and develop increasingly effective cancer therapies.
Competitiondate
201102
Approvedterm2
1 yr 0 mth
Pinamesdelim
Yudin, Andrei
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $85,712~ $74,288~